dwinnex.com

Molina Healthcare, Inc. [NYSE:MOH]: Analyst Rating and Earnings

Equities traders often pay a significant amount of attention to what top market analysts have to say about a potential stock investment. In regards to Molina Healthcare, Inc. [MOH], the most recent average analyst recommendation we can read comes from the fiscal quarter ending in December. On average, stock market experts give MOH an Outperform rating. Its stock price has been found in the range of 13.28 to 38.22. This is compared to its latest closing price of $137.09.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Molina Healthcare, Inc. [MOH] is sitting at 2.50. This is compared to 1 month ago, when its average rating was 2.47.

For the quarter ending in Dec-18 Molina Healthcare, Inc. [MOH] generated $4.66 billion in sales. That’s 2.35% higher than the average estimate of $4.56 billion as provided by Wall Street analysts. The three indicators above suggest that overall, this stock is demonstrating a mixed bag of positive appeal and some drawbacks, making it a somewhat risky investment that also has the potential to generate high ROI in the long run.

Keep your eyes on this company’s next financial results, which are scheduled to be made public on Mon 29 Apr (In 75 Days).

Fundamental Analysis of Molina Healthcare, Inc. [MOH]

Now let’s turn to look at profitability: with a current Operating Margin for Molina Healthcare, Inc. [MOH] sitting at +0.75, this company’s Net Margin is now 1.30%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.

This company’s Return on Total Capital is 4.38, and its Return on Invested Capital has reached -11.40%. Its Return on Equity is -34.29, and its Return on Assets is -6.43. These metrics show a mixed bag, which means that this investment’s attractiveness can be quickly increased or decreased in the short term, depending on future updates MOH financial performance.

Turning to investigate this organization’s capital structure, Molina Healthcare, Inc. [MOH] has generated a Total Debt to Total Equity ratio of 162.23. Similarly, its Total Debt to Total Capital is 61.87, while its Total Debt to Total Assets stands at 25.61. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 113.39, and its Long-Term Debt to Total Capital is 43.24. This company is not leveraging its assets to take on debt, which stunts its growth and limits the ROI for investors.

What about valuation? This company’s Enterprise Value to EBITDA is 5.44. The Enterprise Value to Sales for this firm is now 0.38, and its Total Debt to Enterprise Value stands at 0.34. Molina Healthcare, Inc. [MOH] has a Price to Book Ratio of 3.44, a Price to Cash Flow Ratio of 5.34 and P/E Ratio of 12.23. These metrics all suggest that Molina Healthcare, Inc. is more likely to generate a positive ROI.

Shifting the focus to workforce efficiency, Molina Healthcare, Inc. [MOH] earns $994,150 for each employee under its payroll. Similarly, this company’s Total Asset Turnover is 2.50. This publicly-traded organization’s liquidity data is also interesting: its Current Ratio is 1.35.

Performance Indicators

Let’s now turn our attention to trading performance: Molina Healthcare, Inc. [MOH] has 62.80M shares outstanding, amounting to a total market cap of $8.13B. Its stock price has been found in the range of 71.07 to 154.06. At its current price, it has moved by -16.01% from its 52-week high, and it has moved 82.06% from its 52-week low.

This stock’s Beta value is currently 1.69, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 40.34. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Molina Healthcare, Inc. [MOH] a Reliable Buy?

Shares of Molina Healthcare, Inc. [MOH], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.